Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome

Jennifer Lee¹, Hong-Ki Min², Ji-Won Kim³, Seung-Ki Kwok⁴ and Sung-Hwan Park⁵, ¹Rheumatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ⁴Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul., Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biomarkers and salivary hypofunction, Sjogren's syndrome

Session Information

Date: Monday, October 22, 2018

Session Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Despite advances in the understanding of the pathogenesis, disease-specific biomarkers have not been included in the classification criteria for Primary Sjogren’s syndrome (pSS). Based on the microarray of peripheral blood mononuclear cell (PBMC) of pSS patients, we aimed to investigate whether sialic acid-binding immunoglobulin-like lectin (siglec)-5 might serve as a biomarker for pSS.

Methods:

Microarray of PBMCs obtained from 26 pSS patients and 10 healthy control (HC)s was performed to screen potential biomarkers for pSS. The concentration of siglec-5/14 in saliva and sera was determined by ELISA. Clinical parameters related with pSS were obtained from pSS registry and correlation with salivary siglec-5/14 level was evaluated. Receiver operating curve (ROC) analysis was performed to determine cut off value. A separate validation cohort consisted of subjects with suspicious pSS was evaluated to determine the performance.

Results:

The level of salivary siglec-5/14 was significantly higher in pSS patients compared with HCs or sicca patients (1346.8 [202.8-4280.0] pg/mL, 6.08 [0-134.0] pg/mL, and 0 [0-385.3] pg/mL, median [interquartile range], P<0.001), meanwhile the serum level was not different between the groups. Clinical parameters were available in 170 patients in pSS registry. Salivary siglec-5/14 level negatively correlated with salivary flow rate (spearman’s rho: -0.420, P<0.001), and positively correlated with ocular surface score (rho: 0.331, P<0.001) and serum immunoglobulin G level (rho = 0.202, P=0.008). However, the level of salivary siglec-5/14 was not correlated with ESSDAI or focus score. On ROC analysis, area under the curve was 0.835(0.782-0.888). With cut off value 200pg/mL, sensitivity and specificity was 0.75 and 0.75 respectively. In validation cohort where patients without sicca symptom but have 1 or more positive items in ESSDAI were included, sensitivity and specificity of siglec-5/14 was 68.2% and 71.7%, respectively.

Conclusion:

The level of soluble siglec-5/14 is significantly increased in the saliva of pSS patients and reflects the severity of hyposalivation and ocular surface damage. Although the mechanism of the contribution to gland dysfunction is unclear yet, this easily obtainable salivary biomarker may add benefits on the diagnosis of pSS.

Disclosure: J. Lee, None; H. K. Min, None; J. W. Kim, None; S. K. Kwok, None; S. H. Park, None.

To cite this abstract in AMA style:

Lee J, Min HK, Kim JW, Kwok SK, Park SH. Soluble Siglec-5 Is a Novel Salivary Biomarker for Primary Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/soluble-siglec-5-is-a-novel-salivary-biomarker-for-primary-sjogrens-syndrome/. Accessed March 21, 2023.

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/soluble-siglec-5-is-a-novel-salivary-biomarker-for-primary-sjogrens-syndrome/